Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Is neglect of self-clearance biassing TB vaccine impact estimates?.
SCARPONI, D; CLARK, RA; Weerasuriya, C; EMERY, JC; HOUBEN, RM; WHITE, RG; MCCREESH, N;
2023
medRxiv (2023). 10.1101/2023.04.11.23288400.
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study.
CLARK, RA; Mukandavire, C; Portnoy, A; WEERASURIYA, CK; Deol, A; SCARPONI, D; Iskauskas, A; Bakker, R; Quaife, M; Malhotra, S; Gebreselassie, N; Zignol, M; Hutubessy, RC W; Giersing, B; JIT, M; Harris, RC; Menzies, NA; WHITE, RG;
2023
The Lancet. Global health, (2023).11 4 10.1016/s2214-109x(23)00045-1.
Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment.
Rangaka, MX; Frick, M; Churchyard, G; García-Basteiro, AL; Hatherill, M; Hanekom, W; Hill, PC; Hamada, Y; Quaife, M; Vekemans, J; WHITE, RG; Cobelens, F;
2023
The Lancet. Respiratory medicine, (2023).11 4 10.1016/s2213-2600(23)00084-x.
Demonstrating multi-country calibration of a tuberculosis model using new history matching and emulation package - hmer.
SCARPONI, D; Iskauskas, A; CLARK, RA; Vernon, I; McKinley, TJ; Goldstein, M; Mukandavire, C; Deol, A; Weerasuriya, C; Bakker, R; WHITE, RG; MCCREESH, N;
2023
Epidemics, (2023).43, 10.1016/j.epidem.2023.100678.
New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01 E and BCG-revaccination.
CLARK, RA; Weerasuriya, CK; Portnoy, A; Mukandavire, C; Quaife, M; Bakker, R; SCARPONI, D; Harris, RC; Rade, K; Mattoo, SK; Tumu, D; Menzies, NA; WHITE, RG;
2023
medRxiv (2023). 10.1101/2023.02.24.23286406.
Cost-effectiveness of tuberculosis infection prevention and control interventions in South African clinics: a model-based economic evaluation informed by complexity science methods.
BOZZANI, FM; MCCREESH, N; Diaconu, K; GOVENDER, I; WHITE, RG; Kielmann, K; GRANT, AD; VASSALL, A;
2023
BMJ Global Health, (2023).8 2 10.1136/bmjgh-2022-010306.
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
Portnoy, A; CLARK, RA; Quaife, M; WEERASURIYA, CK; Mukandavire, C; Bakker, R; Deol, AK; Malhotra, S; Gebreselassie, N; Zignol, M; Sim, SY; Hutubessy, RC W; Baena, IG; Nishikiori, N; JIT, M; WHITE, RG; Menzies, NA;
2023
PLOS Medicine, (2023).20 1 10.1371/journal.pmed.1004155.
Updating age-specific contact structures to match evolving demography in a dynamic mathematical model of tuberculosis vaccination.
WEERASURIYA, CK; Harris, RC; MCQUAID, CF; Gomez, GB; WHITE, RG;
2022
PLoS Computational Biology, (2022).18 4 10.1371/journal.pcbi.1010002.
The impact of alternative delivery strategies for novel tuberculosis vaccines in low- and middle-income countries: a modelling study.
CLARK, R; Mukandavire, C; Portnoy, A; WEERASURIYA, C; Deol, A; Scarponi, D; Iskauskas, A; Bakker, R; Quaife, M; Malhotra, S; Gebreselassie, N; Zignol, M; Hutubessy, RC W; Giersing, B; JIT, M; Harris, R; Menzies, N; WHITE, R;
2022
medRxiv (2022). 10.1101/2022.04.16.22273762.
Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis.
LIU, Y; PEARSON, CA B; Sandmann, FG; BARNARD, RC; Kim, J-H; CMMID COVID-19 Working Group,; FLASCHE, S; JIT, M; ABBAS, K;
2022
The Lancet Regional Health - Europe, (2022).17, 10.1016/j.lanepe.2022.100381.